RMS™ MEDICAL PRODUCTS

FREEDOM60® Syringe Infusion System

FreedomEdge® Syringe Infusion System

HIgH•Flo™ Subcutaneous Safety Needle Sets

HIgH•Flo Super26™ Subcutaneous Safety Needle Sets

precision FLOW RATE TUBING™

INVESTOR PRESENTATION

LD MICRO INVITATIONAL
June 5, 2019

OTCQX: REPR

Improving the Patient Experience

DISCLAIMER & NON-GAAP MEASURES

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "plan," "goal," "seek," “vision, “confident,” "future," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our Strategic Plan and other goals. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Non-GAAP Adjusted EBITDA

Adjusted EBITDA excludes from net loss: tax (benefit)/expense, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes, litigation costs, and stock compensation expense.

Non-GAAP Measures

This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measures is included in this presentation.

Mission Statement

To improve the quality of life of patients around the world through the development and delivery of high quality, innovative and easy-to-use infusion products

- RMS Medical's Freedom products primarily used for Subcutaneous (SCIg) and IV (IVIg) Immunoglobulin therapy
- Capitalizing on the ongoing shift from institutional care to lower-cost home and alternative site settings
- Serve specialty pharmacies (US) and collaborate with pharmaceutical companies to promote Ig therapy
- Razor / razorblade model drives recurring revenue
- Refreshed management team driving growth through market development and product innovation initiatives

INVESTMENT HIGHLIGHTS

- Participating in **growing global immunoglobulin** therapy market
- **Increasing net sales** and **expanding gross margin**
- **Strategic plan launched in February 2019** to become the preferred drug delivery partner for specific infusion therapies in select markets
- Strong balance sheet with **no debt** and **simple capital structure**
- Robust supply chain and **strong financial position** to support growth

2018 Highlights ($ in millions)





*Adjusted EBITDA excludes from net income: tax (benefit)/expense, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes and stock compensation expense. For a reconciliation of non-GAAP Adjusted EBITDA to GAAP net income, see Appendix.

Q1 2019: FIRST-EVER $5 MILLION NET SALES QUARTER ($ in MMs)

Q1 2019 v. Q1 2018

- 23.3% rise in net sales – a quarterly record
- Gross margin of 61.3%
- 10.4% increase in Adjusted EBITDA



- Adjusted EBITDA excludes from net loss: tax (benefit)/expense, depreciation and amortization, interest income, operating expenses associated with the Company's organizational changes, litigation costs, and stock compensation expense. For a reconciliation of non-GAAP Adjusted EBITDA to GAAP net income, see Appendix.

No Debt

Access to $1.5 M Credit Facility

	March 31, 2019	December 31, 2018
Cash & Cash Equivalents	$ 2.6 M	$ 3.7 M
Certificates of Deposit	$ 1.5 M	$ 1.5 M
Total Cash, Cash Equivalents and Certificates of Deposit	$ 4.1 M	$ 5.2 M
Shareholders' Equity	$ 9.2 M	$ 9.0 M

Simple Capitalization Structure



- 38.2 M Basic Shares Outstanding
- 3.5 M Options Outstanding / WAEP $1.17
- 1.0 M Warrants / WAEP $0.45 / Exp. August 2019

STRENGTHENED, SEASONED LEADERSHIP DRIVING GROWTH

Don Pettigrew
President & CEO
Joined RMS 2018

23
years experience

Moog, Inc., Baxter (formerly Gambro), and Boston Scientific

Karen Fisher, CPA
CFO
Joined RMS 2015

25
years experience

Armored Autogroup, Gilman Ciocia, The New York Times and Thomson Financial



Manny Marques
COO
Joined RMS 2015

23
years experience

Noble Biocare Procera, LCC

Holds two U.S. patents for cardiovascular medical devices

Brian Schiller, Ph.D.
VP Medical Affairs
Joined RMS 2019

20
years experience

Sanofi (Genzyme)

Avanir Pharmaceuticals, Amgen and Bristol Myers Squibb

Dan Goldberger
Executive Chairman
Joined RMS 2018

Industry veteran, CEO of :

Synergy Disc Replacement, Milestone Medical, Xtant Medical Holdings, and Sound Surgical Technologies

BOARD OF DIRECTORS

Daniel S. Goldberger
Executive Chairman
2018

Joseph M. Manko, Jr.
Lead Director 2018
Director 2016

David. W. Anderson
Director
2016

Robert T. Allen, CPA
Director
2018

James M. Beck
Director
2018

Kathy S. Frommer
Director
2019



R. John Fletcher
Director
2019

IMMUNOGLOBULIN (Ig) THERAPY

- Used in treatment of 350+ diseases and conditions
- Ig replacement therapy is generally administered either intravenously (IVIg) or subcutaneously (SCIg)
  - IVIg infusions are usually given every 3-4 weeks, generally at hospital or infusion center
  - SCIg infusions are typically given daily or weekly, allowing patients to infuse at home on their own schedule
- Rising incidence of autoimmune, neurological, hematological disorders
- **Demand outpacing supply**: In response, pharma companies are investing in plasma collection networks

CSL Behring
Hizentra® Immune Globulin Subcutaneous (Human) 20% Liquid
bpl Bio Products Laboratory
SUBGAM
Takeda
GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10%
HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
KENDRION
gammaked™ immune globulin injection (human), 10% caprylate/chromatography purified
Subcuvia
Cuvitru [Immune Globulin Subcutaneous (Human)] 20%
GRIFOLS
octapharma plasma®
gamunex-C® immune globulin injection (human), 10% caprylate/chromatography purified
gammanorm®

SUBSTANTIAL ADDRESSABLE MARKET

Total Available Market (TAM)

Global Home Infusion Therapy Market
+7% CAGR to $38.7 B by 2026 (1)

Serviceable Available Market (SAM)

$7.0 B U.S. Home Infusion Therapy Market
+10% CAGR (2018 -2024) (2)

$1.1 B North America Market for SCIg,
+12% CAGR (2015-2024) (3)

OUS estimated to be >2X North America (4)

RMS Target Market

$500 M U.S. Home Infusion Equipment Market (5)

RMS Net Sales

FY 2018: $17.4 M Net Sales, +12.4% YOY

Q1 2019: $5.0 M Net Sales, +23.3% YOY

(1) Grand View Research; (2) Global Market Insights; (3) Transparency Market Research; (4) Company Estimate; (5) MSD Healthcare Solutions

We are operating in two of the largest market segments approved for Ig therapy



Primary Immunodeficiency Disease (PIDD)

350+ chronic disorders

270,000 U.S. patient population. (1)

70,000 patients are receiving Ig therapy today.(2)

20,000 patients are receiving SCIg with the RMS FREEDOM system. (3)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A neurological disorder

~25,000 U.S. patient population (2)

2018: Hizentra® becomes first and only SCIg for treatment of CIDP.

(1) Immune Deficiency Foundation; (2) Industry research; (3) RMS estimates

Allows Patients to Self-Administer Therapy

- Slow release of Immunoglobulin into body's circulation avoids serum peaks and troughs
- More attractive to patients with poor venous access
- Less nursing time, fewer systemic adverse events
- Patient flexibility / autonomy
- Patients on SCIg therapy miss significantly fewer days of work/school, and spend significantly less time in the hospital (1)
- Established reimbursement profile

SCIg vs IVIg (2)

Serum levels are more consistent with SCIg over 21 days



(1) Allergy, Asthma, and Clinical Immunology article; Sept 2015; www.ncbi.nlm.nih.gov/pmc/articles/PMC4587876/

(2) P&T Product Profiler – Hizentra Vol. 35, Issue 8 / August 2010 Section 2 / adapted from Berger 2004. Available at http://www.ptcommunity.com/ptjournal/fulltext/ Profiler_Hizentra/Profiler_Hizentra.pdf

RMS MEDICAL'S FREEDOM INTEGRATED INFUSION SYSTEM

- Fully-integrated mechanical system cleared by FDA (August 2017)
- 16 patents and patents pending
- Proven history and safety profile
- Broadly indicated as an infusion system, specifically indicated for SCIg and IVIg infusions, and certain antibiotics
- Well-positioned for the accelerating adoption of SCIg, including Hizentra® and Cuvitru ™
- In clinical trials for other indications and therapies



FREEDOM60®
Syringe Infusion System

FreedomEdge®
Syringe Infusion System

Mechanical syringe pumps are a widely adopted and preferred SCIg delivery system

Dynamic Equilibrium maintains safe pressure of 13.5 psi throughout infusion

Maintenance-free

No batteries or electricity required

Highly-accurate at any fill volume

Low residual volume = minimal drug waste

Easy-to-use, easy-to train

RMS Medical's Freedom60® is featured at www.hizentra.com and in a national advertising campaign for Hizentra® SCIg therapy

FREEDOM60®
Syringe Infusion System

Source: www.hizentra.com

PROPRIETARY TUBING & NEEDLE SETS



precision FLOW RATE TUBING™

- 20+ flow rate options
- Precise infusion rates for the Freedom syringe drivers to deliver a variety of infusion administration times
- Uniform flow profile with no free-flow, bolus or overdose
- Low residual volumes (< 0.01 – 0.09 ml) as compared to competing products (> 0.10 - 0.25 ml) minimizes drug waste



HIgH-Flo™ Subcutaneous Safety Needle Sets

- 24 & 26 gauge
- 4,6,9,12,14 mm length options
- Designed specifically for Freedom syringe driver
- Proprietary needle design minimizes tissue damage, scarring and local site reactions promoting faster healing
- Reduces tissue saturation at site

Each new patient to RMS generates ~$750 per year in recurring revenue

- **Newly diagnosed PIDD patients expected to be prescribed SCIg therapy**

  270,000 patients today [2]

- **PIDD transitioning from IVIg therapy to SCIg therapy**

  70,000 patients today [1]

- **Expanded indications for immunoglobulins delivered with the Freedom system**

  CIDP: 25,000 patients in US [1]

- **Pharmaceutical companies developing subcutaneous administration indications for large molecules and biosimilars using the Freedom system**

  1.0 M patients [1]

(1) Industry research, RMS estimate; (2) Immune Deficiency Foundation

STRATEGIC PLAN

TO BECOME THE PREFERRED DRUG DELIVERY PARTNER FOR SPECIFIC INFUSION THERAPIES IN SELECT MARKETS

FINANCIAL GOALS

$50M Net Revenue Run Rate by end of 2022	Gross Margin of 70%+ by end of 2022	20%+ Annual Organic Revenue Growth for each year

Phase 1

Grow & Harvest

2019 - 2020

- Maintain baseline business
- Penetration of PIDD and CIDP
  - ***Pharma reps***
  - ***Home infusion sales reps***
  - ***Distributors***
- New product development/ launch
- New indications
- Government partnership
- OUS development
- Pharma collaboration
- Funnel of clinical trials
- Margin improvement

Phase 2

Expand & Innovate

2020 - 2021

- Continued execution of Phase 1
- New products
- Expanded indications
- Post-acute care
- European expansion

Phase 3

Accelerated Growth

2021 - Beyond

- Continued Phase 1 & 2 execution
- New drugs and indications
- Post-acute care growth
- Global expansion
- Market share gains

CONCLUDING REMARKS

- Well-respected family of products
- Addressable markets experiencing double-digit growth
- Significant market share with multiple expansion catalysts
- Clean balance sheet, liquidity and simple cap structure
- Refreshed and focused management and leadership team
- Razor – razorblade model drives recurring revenue

APPENDIX

Q1 2019 FINANCIAL SUMMARY

	Three Months Ended 3/31/19	Three Months Ended 3/31/18
Net Sales	**$ 5.0 M**	$ 4.0 M
Gross Profit	**$ 3.0 M**	$ 2.5 M
Gross Margin	**61.3%**	61.1%
Total Operating Expenses	**$ 3.2 M**	$ 2.0 M
Net (Loss) Income	**$(0.1) M**	$ 0.4 M
Non-GAAP Adjusted EBITDA	**$ 0.9 M**	$ 0.8 M

NON-GAAP RECONCILIATION

RECONCILIATION OF GAAP NET (LOSS)/INCOME TO NON-GAAP ADJUSTED EBITDA:		Three Months Ended March 31,		
		2019		2018
GAAP Net (Loss)/Income	$	(85,390)	$	403,427
Tax (Benefit)/Expense		(22,099)		107,741
Depreciation/Amortization		83,651		74,578
Interest Income, Net		(17,480)		(615)
Reorganization Charges		354,926		72,551
Litigation		492,515		155,800
Stock Compensation Expense		121,875		27,183
Non-GAAP Adjusted EBITDA	$	927,998	$	840,665

NON-GAAP RECONCILIATION

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA:		Twelve Months Ended December 31,		
		2018		2017
GAAP Net Income	$	910,570	$	819,547
Tax (Benefit)/Expense		266,380		390,799
Depreciation/Amortization		309,263		306,562
Interest Income, Net		(28,104)		(3,743)
Reorganization Charges		996,447		--
Stock Compensation Expense		293,040		66,947
Non-GAAP Adjusted EBITDA	$	2,747,596	$	1,580,112

RMS™ MEDICAL PRODUCTS

FREEDOM60® Syringe Infusion System

FreedomEdge® Syringe Infusion System

HIgH•Flo™ Subcutaneous Safety Needle Sets

HIgH•Flo Super26™ Subcutaneous Safety Needle Sets

precision FLOW RATE TUBING™

INVESTOR PRESENTATION

LD MICRO INVITATIONAL
June 5, 2019

OTCQX: REPR

Improving the Patient Experience